Fertility-preserving treatment for endometrial atypical hyperplasia and endometrial cancer: a systematic review and meta-analysis
The pooled CR rate of patients who received fertility‑preserving treatment is 0.78.
The systematic review and meta-analysis summarized oncological and reproductive outcomes of patients with endometrial cancer (EC) and endometrial atypical hyperplasia (EAH) undergoing progestin-based fertility‑preserving treatments, comparing different regimens.
This figure reflects the overall effectiveness of conservative progestin‑based therapies in preserving fertility among women with early‑stage endometrial carcinoma.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Immunotherapy improves endometrial cancer outcomes
- Quality of Life Measures in Advanced Endometrial Cancer: A Systematic Review of Reporting Practices in Phase III Clinical Trials
- Endometrial Cancer - PMC
- Current recommendations and recent progress in endometrial cancer
- Advancements in Endometrial Cancer Research in 2024